Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
about
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemiaPrognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-AnalysisAn update of current treatments for adult acute myeloid leukemiaMolecular Genetic Markers in Acute Myeloid LeukemiaCore Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic OpportunitiesMinimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaRUNX1 truncation resulting from a cryptic and novel t(6;21)(q25;q22) chromosome translocation in acute myeloid leukemia: A case reportMeasurable residual disease testing in acute myeloid leukaemia.Future prospects of therapeutic clinical trials in acute myeloid leukemia.Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Minimal residual disease in acute myeloid leukaemiaBack to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Acute myeloid leukemia: 2014 update on risk-stratification and management.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.A multigene array for measurable residual disease detection in AML patients undergoing SCTGemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.Frontline treatment of acute myeloid leukemia in adults.Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.Acute myeloid leukemia: 2016 Update on risk-stratification and management.Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.Minimal Residual Disease in Acute Myeloid Leukemia.Molecular landscape in acute myeloid leukemia: where do we stand in 2016
P2860
Q26771438-F2D1564D-1BE8-4319-8AFC-A7BC84F23347Q26771740-B03B6059-2B51-4F1C-A15D-AA30110454F3Q26776396-F08E02DE-366C-40DA-8316-722769470FD4Q26799606-70DE5C35-6409-4713-BE88-222C6605DE18Q26863756-81EBBA15-2E0F-4A2D-B206-737E8AE374ACQ28073464-AB5B471D-8C1E-4822-928D-3EE8938CEE6CQ28087291-F188FC11-9166-4FCA-8C62-F8540C48A2BBQ28597831-F8839619-5BC5-40DF-B583-32DC1573D04AQ30234914-015A3383-F4D0-4D5E-8DD1-21257C33CDA3Q30244168-D6C8C88E-8B1A-427A-BC28-461B105EF476Q33421005-11ECC816-8A47-4C95-A055-816E61F49077Q33641201-0C83969F-79C3-4B6F-899F-81712CED1ADBQ33758306-CD30F0DE-8065-47C7-B5CD-1D7F1D0C92CBQ33832709-8AF27B5C-CDF0-4629-854C-5DD33AC4B2E3Q34106837-8345BAEE-E998-4E39-B4F5-F82D6E9DDA63Q34179265-1020CF70-2D5D-452C-9F51-36989C8D2C01Q34380489-0127F87C-DD2B-4BA4-ABBB-950290CE945EQ34665691-D16219E4-0B79-43E5-9975-288E963DC8FBQ34715598-EA3FBAC3-8E1C-4F64-B30B-CF5B1D2FC771Q35582360-03BD0776-DF0F-4E8A-A501-1868503F78ADQ35606252-7167C0F0-9D9F-485C-8CE2-BA18BFF200B7Q35669870-0DD21D9D-47F5-48AD-A075-DC6052076731Q35992927-81BDD847-D034-47DD-BCCB-7B34C2413C0FQ36750458-A21BABB4-C8CA-4F17-902C-C4C2F4F9F7D0Q36919799-44488AEE-D9C5-44E4-AD75-604F9230D5B7Q37624593-BB18AAE2-0135-41CC-B469-E8AD5D976D45Q37628021-4E877A21-0196-4514-B394-4EEB33CD46ADQ38104287-ED09E74B-E8E7-4858-871C-F40CFC8FC7F1Q38183943-681C240C-511C-4D31-9803-041B14A17BDFQ38212956-06E29AD4-FCC9-441F-A4C7-21FDFCA768A0Q38240563-E80ADC9A-8C39-48DA-8046-75EB2FEEF7C5Q38263126-D530A94C-FCD2-4F98-AA36-CC27A03C801AQ38494659-6627CCCB-DAFF-4ACB-A72D-02B58BFF049FQ38767583-686C2432-BE9B-48F0-B127-769F20740383Q38791735-E1AA60EB-5E32-41E8-B672-E22C61DF4FE4Q38897289-ED870B82-CEF5-43A1-A3E5-DCD7F32C43F2Q38902497-DBB25102-C12B-4224-9306-05E4038BA7B9Q38904250-D04230E2-83AD-48F8-9BDD-BF34CF79B4FDQ39097771-A7A3541F-65CF-49B2-ADAA-27B3240B9C2BQ39116878-C5338BCF-C687-4656-92F6-CF128F67BBF3
P2860
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Prospective evaluation of gene ...... factor acute myeloid leukemia.
@en
Prospective evaluation of gene ...... factor acute myeloid leukemia.
@nl
type
label
Prospective evaluation of gene ...... factor acute myeloid leukemia.
@en
Prospective evaluation of gene ...... factor acute myeloid leukemia.
@nl
prefLabel
Prospective evaluation of gene ...... factor acute myeloid leukemia.
@en
Prospective evaluation of gene ...... factor acute myeloid leukemia.
@nl
P2093
P50
P1433
P1476
Prospective evaluation of gene ...... factor acute myeloid leukemia.
@en
P2093
Aline Renneville
Arnaud Pigneux
Bruno Lioure
Christian Recher
Christine Terré
Claude-Eric Bulabois
Cécile Pautas
Céline Berthon
Emmanuel Raffoux
Eric Jourdan
P304
P356
10.1182/BLOOD-2012-10-462879
P407
P577
2013-01-15T00:00:00Z